WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims for deep remission in rare blood cancer
Disease control Not yet recruitingThis study is testing a combination of three drugs (zanubrutinib, bendamustine, and a CD20 antibody) for people newly diagnosed with a rare blood cancer called Waldenström macroglobulinemia (WM). The goal is to see how well this combination can achieve deep, lasting responses by …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New trial tests shorter treatment for rare blood cancer
Disease control Not yet recruitingThis early-stage study is testing whether a three-drug combination can effectively control Waldenström Macroglobulinemia when given for a fixed period instead of indefinitely. Researchers will first find the safest dose of one drug, then test that dose in more patients to see how…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC